» Articles » PMID: 34768652

Non-Invasive Risk Prediction Based on Right Ventricular Function in Patients with Pulmonary Arterial Hypertension

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Nov 13
PMID 34768652
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Right ventricular dysfunction is a major determinant of outcome in pulmonary arterial hypertension (PAH). We aimed to identify echocardiographic right heart parameters associated with adverse outcome and to develop a non-invasive, echocardiography-based risk score for PAH patients.

Methods And Results: In 254 PAH patients we analyzed functional status, laboratory results, and echocardiographic parameters. We included these parameters to estimate all-cause death or lung transplantation using Cox regression models. The analyses included a conventional model using guideline-recommended variables and an extended echocardiographic model. Based on the final model a 12-point risk score was derived, indicating the association with the primary outcome within five years. During a median follow-up time of 4.2 years 74 patients died or underwent lung transplantation. The conventional model resulted in a C-Index of 0.539, whereas the extended echocardiographic model improved the discrimination (C-index 0.639, -value 0.017). Ultimately, the newly developed risk score included WHO functional class, 6-min walking distance, N-terminal brain natriuretic peptide concentrations, pericardial effusion, right atrial area, tricuspid annular plane systolic excursion, and fractional area change.

Conclusion: Integrating right heart function assessed by echocardiography improves prediction of death or lung transplantation in PAH patients. Independent validation of this finding is warranted.

Citing Articles

Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.

Lokhorst C, van der Werf S, Berger R, Douwes J J Am Heart Assoc. 2024; 13(13):e034151.

PMID: 38904230 PMC: 11255703. DOI: 10.1161/JAHA.123.034151.


Pulmonary Hypertension: Current Diagnosis, Approach and Treatment at the Dawn of the New European Guidelines.

Orfanos S, Giannakoulas G J Clin Med. 2022; 11(19).

PMID: 36233671 PMC: 9572919. DOI: 10.3390/jcm11195804.

References
1.
Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00889-2017. View

2.
Humbert M, Sitbon O, Simonneau G . Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351(14):1425-36. DOI: 10.1056/NEJMra040291. View

3.
Rosenkranz S, Preston I . Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. Eur Respir Rev. 2015; 24(138):642-52. PMC: 9487613. DOI: 10.1183/16000617.0062-2015. View

4.
Hoette S, Creuze N, Gunther S, Montani D, Savale L, Jais X . RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. Lung. 2018; 196(2):157-164. DOI: 10.1007/s00408-018-0089-7. View

5.
DAlonzo G, Barst R, Ayres S, Bergofsky E, Brundage B, Detre K . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5):343-9. DOI: 10.7326/0003-4819-115-5-343. View